Ozanimod for the treatment of relapsing remitting multiple sclerosis. (12th December 2018)

• Record Type: Journal Article
• Authors: Rasche, Ludwig; Paul, Friedemann
• Is Part Of: Expert opinion on pharmacotherapy. Volume 19:Number 18(2018)
• Page Start: 2073
• Page End: 2086
• Publication Date: 2018-12-12
• Subjects: Ozanimod -- RPC1063 -- sphingosine 1-phosphate receptor (S1PR) -- multiple sclerosis; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2018.1540592
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction: Ozanimod is a selective sphingosine 1-phosphate receptor 1 and 5 modulator under development by Celgene, for the treatment of relapsing remitting multiple sclerosis. Extensive clinical experience has become available for the related compound fingolimod, favoring the sphingosine 1-phosphate therapeutic concept. Off-target effects have been attributed to its low receptor specificity and have prompted the development of next generation sphingosine 1-phosphate receptor modulators. Areas covered: The authors evaluate the literature of ozanimod, using the PubMed database as well as repositories of the European Committee for Treatment and Research in Multiple Sclerosis and the American and European Academy of Neurology. Specifically, the authors cover and discuss the preclinical data on ozanimod, pharmacokinetics and dynamics, and data on efficacy and safety from the pivotal trials. Expert opinion: Superiority of ozanimod over intramuscular interferon β-1a with regard to reduction in annualized relapse rate and magnetic resonance imaging outcomes has been shown in two phase III trials. The beneficial effect on brain volume and gray matter loss are encouraging and in line with data on other newer immunomodulators. Ozanimod is a valuable contribution to the therapeutic armamentarium in MS, although the effect on disability progression is unclear and requires further investigations.